Peregrine Capital Management’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-734,877
| Closed | -$764K | – | 336 |
|
|
2024
Q3 | $764K | Sell |
734,877
-277,758
| -27% | -$289K | 0.02% | 277 |
|
|
2024
Q2 | $1.75M | Sell |
1,012,635
-3,820
| -0.4% | -$6.61K | 0.05% | 252 |
|
|
2024
Q1 | $2.43M | Sell |
1,016,455
-73,506
| -7% | -$176K | 0.07% | 247 |
|
|
2023
Q4 | $3.63M | Sell |
1,089,961
-288,606
| -21% | -$961K | 0.11% | 241 |
|
|
2023
Q3 | $5.16M | Sell |
1,378,567
-58,986
| -4% | -$221K | 0.15% | 227 |
|
|
2023
Q2 | $6.14M | Buy |
1,437,553
+370,369
| +35% | +$1.58M | 0.17% | 229 |
|
|
2023
Q1 | $7.3M | Sell |
1,067,184
-50,298
| -5% | -$344K | 0.21% | 206 |
|
|
2022
Q4 | $8.85M | Sell |
1,117,482
-12,124
| -1% | -$96K | 0.28% | 162 |
|
|
2022
Q3 | $10.9M | Buy |
1,129,606
+52,321
| +5% | +$503K | 0.35% | 87 |
|
|
2022
Q2 | $7.8M | Buy |
1,077,285
+130,226
| +14% | +$943K | 0.24% | 191 |
|
|
2022
Q1 | $12.2M | Buy |
947,059
+206,139
| +28% | +$2.66M | 0.29% | 119 |
|
|
2021
Q4 | $11.8M | Sell |
740,920
-136,365
| -16% | -$2.18M | 0.24% | 156 |
|
|
2021
Q3 | $14.1M | Sell |
877,285
-180,589
| -17% | -$2.9M | 0.29% | 118 |
|
|
2021
Q2 | $14.6M | Buy |
1,057,874
+187,151
| +21% | +$2.59M | 0.26% | 169 |
|
|
2021
Q1 | $12.7M | Sell |
870,723
-31,064
| -3% | -$454K | 0.24% | 211 |
|
|
2020
Q4 | $15.7M | Buy |
901,787
+376,895
| +72% | +$6.55M | 0.3% | 144 |
|
|
2020
Q3 | $9.63M | Buy |
524,892
+79,635
| +18% | +$1.46M | 0.26% | 138 |
|
|
2020
Q2 | $7.95M | Buy |
445,257
+6,366
| +1% | +$114K | 0.23% | 146 |
|
|
2020
Q1 | $7.12M | Sell |
438,891
-4,971
| -1% | -$80.6K | 0.26% | 132 |
|
|
2019
Q4 | $7.99M | Buy |
443,862
+206,771
| +87% | +$3.72M | 0.2% | 173 |
|
|
2019
Q3 | $4.8M | Buy |
+237,091
| New | +$4.8M | 0.13% | 227 |
|